Ion Beam Applications S.A. (IBA) is a global medical technology company headquartered in Louvain-la-Neuve, Belgium, primarily focused on developing advanced solutions for cancer diagnosis and therapy. The company's core expertise lies in particle accelerator technology, where it holds a leading market position in proton therapy systems.
IBA operates through two primary business segments: Proton Therapy and Other Accelerators, and Dosimetry. The Proton Therapy and Other Accelerators segment generates the majority of the company's revenue (approximately 70%) and involves the development, fabrication, and servicing of medical and industrial particle accelerators. This includes turnkey proton therapy systems for precision cancer treatment, cyclotrons used to produce radioisotopes for PET and SPECT imaging, and industrial accelerators used for sterilization and ionization. The Dosimetry segment provides measurement and quality assurance instruments that enhance efficiency and minimize errors in radiation therapy and medical imaging calibration procedures.
Geographically, IBA has a global footprint, with significant revenue contributions from the Rest of the World, the United States, and Europe. The company's business model combines the capital-intensive sale of large-scale medical equipment with recurring revenue streams from long-term service and maintenance contracts, as well as software solutions. IBA's competitive position is underpinned by its extensive installed base of proton therapy centers and continuous investments in research and development, including partnerships to develop novel cancer treatments like Actinium-225 radioisotopes.
